TEHRAN (Iran News) – Spikogen vaccine enters third phase of clinical trial. The Iranian-Australian coronavirus vaccine Spikogen started the third phase of the clinical trial with the participation of 17,000 people on Saturday.
The first phase of the study was performed on volunteer Australians and received the necessary approval, the second phase was administrated to 400 Iranians, which has had no serious side effects, Payam Tabarsi, researcher of the vaccine study project said.
The second human testing showed good results, with 70 percent antibody, he stated, adding, the delta variant is now very strong and many vaccines have not been effective against the mutant.
Vaccines against viruses can be divided into three main categories: live attenuated, inactivated/killed, and subunit vaccines. Recombinant protein subunit vaccines are composed of at least 1 type of viral antigen. These vaccines are significantly more secure than live attenuated and inactivated vaccines.
Iran is also producing vaccines jointly with two countries of Cuba and Russia, which may also be released by September.
The Iranian-made Sputnik vaccine is undergoing the final testing phase, and Pastu Covac received the emergency use license.
Mass vaccination against COVID-19 started on Iranian citizens with the Russian-made Sputnik V vaccine on February 9.
While Iran continues efforts to mass-produce local candidates, over 13 million doses of foreign vaccines have already been imported and others are expected soon.
According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.